الإحصائيات الأساسية
| LEI | 5493008RH0GTKHHPZI77 |
| CIK | 926326 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Omnicell, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 25, 2025 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies FORT WORTH, Texas, - August 25, 2025—Omnicell, Inc. (Nasd |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 6, 2025 |
Exhibit 10.4 Global Performance-Based Restricted Stock Unit Award Omnicell, Inc. Grant Notice 4220 North Freeway Fort Worth, Texas 76137 Name: Employee ID: You have been granted a Performance-Based Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Performance- Based Restricted Stock Unit (“PSU”) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date o |
|
| August 6, 2025 |
Exhibit 10.3 Global Restricted Stock Unit Award Omnicell, Inc. Grant Notice 4220 North Freeway Fort Worth, Texas 76137 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (“RSU”) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Vesting Date Number o |
|
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33 |
|
| August 6, 2025 |
Omnicell, Inc. Executive Bonus Plan (amended and restated May 2025) Exhibit 10.1 OMNICELL, INC. EXECUTIVE BONUS PLAN OBJECTIVES: The objectives of this Omnicell, Inc. Executive Bonus Plan (“Executive Bonus Plan”), effective for performance periods commencing on or after January 1, 2025, are to: 1)Drive earnings predictability and revenue growth; 2)Drive execution of operating plan and strategic objectives; and 3)Motivate and inspire Executives (as defined below) t |
|
| August 6, 2025 |
Omnicell, Inc. Executive Severance Plan (amended and restated May 2025) Exhibit 10.2 OMNICELL, INC. EXECUTIVE SEVERANCE PLAN 1.Purpose. Omnicell, Inc. (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Compensation Committee of the Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly held corporations, the possibili |
|
| July 31, 2025 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Second Quarter 2025 Results Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises fu |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. |
|
| June 18, 2025 |
Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Omnicell, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2009 Equity Incentive Plan Equity |
|
| June 18, 2025 |
Omnicell, Inc. 2009 Equity Incentive Plan, as Exhibit 99.1 OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2009 APPROVED BY THE STOCKHOLDERS: MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 17, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2010 AMENDED BY THE BOARD OF DIRECTORS: MARCH 18, 2013 APPROVED BY THE STOCKHOLDERS: MAY 21, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 13, 2015 APPROVED |
|
| June 5, 2025 |
Separation Agreement dated June 5, 2025 by and between Omnicell, Inc. and Nchacha Etta*+ Exhibit 10.1 June 4, 2025 Nchacha Etta Re: Separation Agreement and General Release Dear Nchacha: This Separation Agreement and General Release (“Agreement”) is made by and between Omnicell, Inc., (“Company”) and the employee signatory below (“you” or “Employee,” together with Company, “Parties”). This Agreement is binding upon your heirs, beneficiaries, successors, executors, administrators, agen |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 22, 2025 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program FORT WORTH, Texas - May 22, 2025 - Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 4220 North Freeway, Fort Worth, Texas 76137 (Address of Principal Executive O |
|
| May 22, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 22, 2025 |
Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2024 to December 31, 2024 Introduction This Conflict Minerals Report (the “Report”) of Omnicell, Inc. (“Omnicell” or the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, |
|
| May 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3 |
|
| May 6, 2025 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces First Quarter 2025 Results Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 n |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 3, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 12, 2025 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Chief Financial Officer Transition Company Reiterates First Quarter and Full Year 2025 Guidance FORT WORTH, Texas – March 12, 2025 - Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “managemen |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 4, 2025 |
Exhibit 10.1 Execution Version Employment Agreement This Employment Agreement (this “Agreement”) is entered into effective as of the 4th day of March, 2025 by and between Omnicell, Inc. and Randall A. Lipps (“Executive”). Unless the context indicates otherwise, the term “Company” means and includes Omnicell, Inc., its successors, assigns, parents, subsidiaries, divisions and affiliates (whether i |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| February 27, 2025 |
Exhibit 19.1 Omnicell, Inc. Policy Against Trading on the Basis of Inside Information During the course of your employment with OMNICELL, INC. or its affiliated entities (collectively, the “Company”), you may receive important information that is not yet publicly available, i.e., not disclosed to the public in a press release or filing with the U.S. Securities and Exchange Commission (“inside info |
|
| February 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Omnicell Pty Ltd Australia Omnicell (Beijing) Technology Co. Ltd China Omnicell GmbH Germany Omnicell SAS France Omnicell S.r.l. Italy Omnicell India Private Limited India Omnicell International Regional Headquarters Middle East and North Africa Saudi Arabia Omnicell Limited United Kingdom Hub and |
|
| February 6, 2025 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA |
|
| February 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2025 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 6, 2025 |
Investor Presentation February 6, 2025 Exhibit 99.2 Investor Presentation February 6, 2025 This presentation contains “forward - looking statements” within the meaning of federal securities laws. These forward - looking sta tements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non - historical information. Without limiting the foregoing, statements including the words |
|
| November 25, 2024 |
Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering Exhibit 99.1 Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering FORT WORTH, Texas – November 20, 2024 – Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutio |
|
| November 25, 2024 |
Form of Confirmation for Purchased Options Exhibit 10.1 Bidding Form [Dealer Name] [Dealer Address] [], 2024 To: Omnicell, Inc. [] [] [] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [] (“Dealer”) and Omnicell, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). T |
|
| November 25, 2024 |
Form of Confirmation for Warrants Exhibit 10.2 Bidding Form THE SECURITIES REPRESENTED HEREBY (THE “WARRANTS”) WERE ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE WARRANTS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN APPLICABLE EXEMPTION FROM THE REG |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| November 25, 2024 |
Exhibit 4.1 OMNICELL, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 22, 2024 1.00% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions 1 Section 1.02 . References to Interest 15 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01 . Designation and Amount 15 |
|
| November 18, 2024 |
Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes Exhibit 99.1 Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes FORT WORTH, Texas – November 18, 2024 – Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “of |
|
| November 18, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| November 18, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “First Amendment”), dated as of November 18, 2024, is entered into by and among OMNICELL, INC., a Delaware corporation (the “Borrower”), each Lender party hereto, and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as admini |
|
| November 8, 2024 |
, Inc. and Nnamdi Njoku dated August 15, 2024 Exhibit 10.1 August 15, 2024 Nnamdi Njoku Dear Nnamdi, On behalf of Randall Lipps, and Omnicell’s Board of Directors, Omnicell, Inc. (the “Company”) is pleased to offer you the role of Executive Vice President and Chief Operating Officer (COO) reporting directly to Randall Lipps as our Chairman, President, CEO and Founder. Your target start date for employment is tentatively planned for October 7, |
|
| November 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| October 30, 2024 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Third Quarter 2024 Results Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 25, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| September 25, 2024 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation an |
|
| August 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33 |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 1, 2024 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Second Quarter 2024 Results Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per di |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Omnicell, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2009 Equity Incentive Plan Equity |
|
| June 21, 2024 |
Omnicell, Inc. 2009 Equity Incentive Plan, as amended Exhibit 99.1 OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2009 APPROVED BY THE STOCKHOLDERS: MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 17, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2010 AMENDED BY THE BOARD OF DIRECTORS: MARCH 18, 2013 APPROVED BY THE STOCKHOLDERS: MAY 21, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 13, 2015 APPROVED |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporatio |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 4220 North Freeway, Fort Worth, Texas 76137 (Address of Principal Executive O |
|
| May 14, 2024 |
Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2023 to December 31, 2023 Introduction This Conflict Minerals Report (the “Report”) of Omnicell, Inc. (“Omnicell” or the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, |
|
| May 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3 |
|
| May 7, 2024 |
Omnicell, Inc. Executive Bonus Plan OMNICELL, INC. EXECUTIVE BONUS PLAN OBJECTIVES: The objectives of this Omnicell, Inc. Executive Bonus Plan (“Executive Bonus Plan”), effective for performance periods commencing on or after January 1, 2024, are to: 1) Drive earnings predictability and revenue growth; 2) Drive execution of operating plan and strategic objectives; and 3) Motivate and inspire Executives (as defined below) to contribu |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 2, 2024 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces First Quarter 2024 Results Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million FORT WORTH, Texas - May 2, 2024 - Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “w |
|
| April 4, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| February 28, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| February 28, 2024 |
OMNICELL, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Omnicell, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of fina |
|
| February 28, 2024 |
Form of Director and Officer Indemnity Agreement INDEMNITY AGREEMENT This Indemnity Agreement (the “Agreement”) is made and entered into this day of , by and between OMNICELL, INC. |
|
| February 28, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Omnicell Pty Ltd Australia Omnicell (Beijing) Technology Co. Ltd China Omnicell GmbH Germany Omnicell SAS France Omnicell S.r.l. Italy Omnicell India Private Limited India Omnicell B.V. Netherlands Omnicell Limited United Kingdom Hub and Spoke Innovations Limited United Kingdom ateb, Inc. United S |
|
| February 13, 2024 |
OMCL / Omnicell, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01606-omnicellinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Omnicell Inc Title of Class of Securities: Common Stock CUSIP Number: 68213N109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 8, 2024 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results Full Year 2023 GAAP Revenues of $1.147 billion Full Year 2023 GAAP net loss of $20 million and GAAP net loss per diluted share of $0.45 Full Year 2023 Non-GAAP |
|
| January 11, 2024 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Elects Eileen Voynick to Board of Directors Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board FORT WORTH, Texas, - January 11, 2024—Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 11, 2023 |
OMCL / Omnicell, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Omnicell, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68213N109 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| November 9, 2023 |
Separation Agreement dated November 3, 2023 by and between Omnicell, Inc. and Scott P. Seidelmann Exhibit 10.1 November 3, 2023 Re: Scott Seidelmann Separation Agreement Dear Scott: This letter sets forth the substance of the separation agreement (the “Agreement”) that Omnicell, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your employment termination date with the Company will be November 3, 2023 (the “Separation Date”). Starting on June 1, 2023, |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 3, 2023 |
Exhibit 10.3 Global Restricted Stock Unit Award Omnicell, Inc. Grant Notice 4220 North Freeway Fort Worth, Texas 76137 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (RSU) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Fair Market Value per U |
|
| November 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 2, 2023 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Third Quarter 2023 Results; Updates Fiscal Year 2023 Guidance and Announces Reduction in Force Total GAAP revenues of $299 million GAAP net income per diluted share of $0.12 Non-GAAP net income per dilute |
|
| October 16, 2023 |
Exhibit 10.1 Execution Version $350,000,000 SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of October 10, 2023, by and among OMNICELL, INC., as Borrower, the Lenders referred to herein, as Lenders, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender and an Issuing Lender, WELLS FARGO BANK, NATIONAL ASSOCIATION, JPMORGAN CHASE BANK, N.A., PNC BANK, NATIONAL ASSO |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 5, 2023 |
Separation Agreement dated October 4, 2023 by and between Omnicell, Inc. and Christine M. Mellon Exhibit 10.1 October 2, 2023 Christine Mellon Re: Christine Mellon Separation Agreement Dear Christine: This letter sets forth the substance of the separation agreement (the “Agreement”) that Omnicell, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your employment termination date with the Company will be October 1, 2023 (the “Separation Date”). Startin |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| September 11, 2023 |
OMCL / Omnicell, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Omnicell Inc. Title of Class of Securities: Common Stock CUSIP Number: 68213N109 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 10, 2023 |
Separation Agreement dated August 4, 2023 by and between Omnicell, Inc. and Peter J. Kuipers Exhibit 10.1 August 2, 2023 Mr. Peter J. Kuipers EVP & Chief Financial Officer c/o Omnicell, Inc. Re: Peter J. Kuipers Separation Agreement Dear Peter: This letter sets forth the substance of the Separation Agreement (the “Agreement”) that Omnicell, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your employment termination date with the Company will be |
|
| August 4, 2023 |
Exhibit 10.5 Global Restricted Stock Unit Award Omnicell, Inc. Grant Notice 4220 North Freeway Fort Worth, Texas 76137 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (RSU) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Fair Market Value per U |
|
| August 4, 2023 |
Exhibit 10.4 Global Stock Option Award Omnicell, Inc. Grant Notice 4220 North Freeway Fort Worth, Texas 76137 Name Employee ID: You have been granted an option to purchase Omnicell, Inc. Common Stock as follows: Type of Option: Non-Qualified Stock Option Grant No.: Stock Option Plan: 2009 Equity Incentive Plan Date of Grant: Grant Expiration Date: Total Number of Option Shares: Option Price per Sh |
|
| August 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33 |
|
| August 4, 2023 |
Offer Letter between Omnicell, Inc. and Nchacha E. Etta dated April 30, 2023 Exhibit 10.3 April 30, 2023 Mr. Nchacha Etta Dear Nchacha, On behalf of Randall Lipps, and Omnicell’s Board of Directors, Omnicell, Inc. (the “Company”) is pleased to offer you the role of Executive Vice President and Chief Financial Officer reporting directly to Randall Lipps as our Chairman, President, CEO and Founder. Your target start date for employment is tentatively planned for May 15th, wh |
|
| August 3, 2023 |
Omnicell, Inc. Executive Severance Plan Exhibit 10.1 OMNICELL, INC. EXECUTIVE SEVERANCE PLAN 1.Purpose. Omnicell, Inc. (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Compensation Committee of the Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly held corporations, the possibili |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 1, 2023 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces Second Quarter 2023 Results Total GAAP revenues of $299 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.57 FORT WORTH, Texas - August 1, 2023 - Omnicell, Inc |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 11, 2023 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Appoints Bobby Ghoshal to Board of Directors Established Leader Brings Global SaaS and Healthcare Technology Experience to Board FORT WORTH, Texas, - July 11, 2023—Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leader in transformin |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporatio |
|
| May 30, 2023 |
Omnicell Announces Leadership and Organizational Changes Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Announces Leadership and Organizational Changes FORT WORTH, Texas, - May 30, 2023—Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced changes to its leadership str |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 26, 2023 |
Omnicell, Inc. Amended and Restated 1997 Employee Stock Purchase Plan, as amended Exhibit 99.1 OMNICELL, INC. AMENDED AND RESTATED 1997 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS MARCH 18, 1997 APPROVED BY STOCKHOLDERS MARCH 6, 1998 AMENDED BY THE BOARD OF DIRECTORS APRIL 19, 2000 AMENDMENT APPROVED BY STOCKHOLDERS APRIL 16, 2001 AMENDED BY THE BOARD OF DIRECTORS MARCH 5, 2009 AMENDMENT APPROVED BY STOCKHOLDERS MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 26, 2023 |
Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Omnicell, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2009 Equity Incentive Plan Equity |
|
| May 26, 2023 |
As filed with the Securities and Exchange Commission on May 26, 2023 As filed with the Securities and Exchange Commission on May 26, 2023 Registration No. |
|
| May 26, 2023 |
Omnicell, Inc. 2009 Equity Incentive Plan, as amended Exhibit 99.2 OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2009 APPROVED BY THE STOCKHOLDERS: MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 17, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2010 AMENDED BY THE BOARD OF DIRECTORS: MARCH 18, 2013 APPROVED BY THE STOCKHOLDERS: MAY 21, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 13, 2015 APPROVED |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 4220 North Freeway, Fort Worth, Texas 76137 (Address of Principal Executive O |
|
| May 25, 2023 |
Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2022 to December 31, 2022 Introduction This Conflict Minerals Report (the “Report”) of Omnicell, Inc. (“Omnicell” or the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 15, 2023 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations [email protected] 650-435-3318 Omnicell Appoints Nchacha E. Etta as Executive Vice President and Chief Financial Officer Seasoned Leader Brings Over Two Decades of Finance and Accounting Experience to Omnicell FORT WORTH, Texas, - May 15, 2023—Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” o |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3 |
|
| May 2, 2023 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 [email protected] Omnicell Announces First Quarter 2023 Results Total GAAP revenues of $291 million GAAP net loss per diluted share of $0.33 Non-GAAP net income per diluted share of $0.39 FORT WORTH, Texas - May 2, 2023 - Omnicell, Inc. (NAS |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) x Filed by the Registrant ¨ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| April 6, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 3, 2023 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Second Amendment”), dated as of March 29, 2023, is entered into by and among OMNICELL, INC., a Delaware corporation (the “Borrower”), each Subsidiary Guarantor (as defined in the Amended Credit Agreement (as defined below)) party hereto, the |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| March 1, 2023 |
Promotion letter between Omnicell, Inc. and Corey J. Manley dated May 18, 2022 Exhibit 10.31 May 18, 2022 Personal & Confidential Mr. Corey J. Manley SVP, Chief Legal Officer & Corporate Secretary C/O Omnicell, Inc. Re: Promotion to SVP, Chief Legal Officer & Corporate Secretary Dear Corey, On behalf of Randy Lipps and the Board of Directors (“Board”) of Omnicell, Inc. (“Omnicell” or the “Company”), I am pleased to report that you are being promoted to the position of Senior |
|
| March 1, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Omnicell Pty Ltd Australia Omnicell (Beijing) Technology Co. Ltd China Omnicell GmbH Federal Republic of Germany Omnicell SAS France Omnicell S.r.l. Italy Omnicell India Private Limited India Omnicell B.V. Netherlands Omnicell Limited United Kingdom Hub and Spoke Innovations Limited United Kingdom |
|
| February 28, 2023 |
February 28, 2023 Investor Relations Exhibit 99.2 February 28, 2023 Investor Relations © 2023 Omnicell, Inc. Forward - Looking Statements 2 This presentation contains “forward - looking statements” within the meaning of federal securities laws. These forward - looking sta tements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other non - historical information. Without lim |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| February 28, 2023 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 2625 Augustine Drive, Suite 301 650-435-3318 Santa Clara, CA 95054 [email protected] Omnicell Announces Fiscal Year and Fourth Quarter 2022 Results 2022 Total Bookings of $1.054 billion Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion Ended Year with Over 150 Long |
|
| February 9, 2023 |
OMCL / Omnicell, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01575-omnicellinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Omnicell Inc. Title of Class of Securities: Common Stock CUSIP Number: 68213N109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| February 6, 2023 |
OMCL / Omnicell, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Omnicell, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68213N109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 30, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000- |
|
| November 2, 2022 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 2625 Augustine Drive, Suite 301 650-435-3318 Santa Clara, CA 95054 [email protected] Omnicell Announces Financial Results for Third Quarter 2022 GAAP and non-GAAP revenues of $348 million GAAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 SANTA CLARA, Cal |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 21, 2022 |
Third Amended and Restated Bylaws of Omnicell, Inc. Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF OMNICELL, INC. (A DELAWARE CORPORATION) Effective as of October 17, 2022 TABLE OF CONTENTS ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS' MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 1 |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 20, 2022 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Senior Vice President, Investor Relations 650-435-3318 [email protected] Omnicell Highlights Differentiated Strategy and Unique Business Model at 2022 Investor Day Advanced Services Business Model Driving Growth Opportunities and Recurring, High Visibility Revenue Well Positioned in Large and Growing Market Segments Santa Clara |
|
| September 20, 2022 |
Investor Day September 2022 Positioning Omnicell for the Future © 2022 Omnicell, Inc. 1 Exhibit 99.1 Investor Day September 2022 Positioning Omnicell for the Future ? 2022 Omnicell, Inc. 1 ? 2022 Omnicell, Inc. Agenda Welcome Kathleen Nemeth, Senior Vice President, Investor Relations Strategic Overview & Opportunity Randall Lipps, Chairman, President, Chief Executive Officer & Founder Pharmacy Transformation & the Shift to Services Scott Seidelmann, Executive Vice President & Chief C |
|
| September 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| September 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2022 |
Letter agreement between Omnicell, Inc. and Dan S. Johnston, dated July 29, 2022 Exhibit 10.2 July 29, 2022 Personal & Confidential Dan S. Johnston EVP & Executive Advisor C/O Omnicell, Inc. Re: Omnicell Medical Benefit Plan Coverage Continuation Dear Dan, In recognition and consideration of your many years of outstanding leadership and exceptional service to Omnicell, Inc. (?Omnicell? or the ?Company?), the Company agrees to provide you continued participation in Omnicell?s M |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 4, 2022 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 2625 Augustine Drive, Suite 301 650-435-3318 Santa Clara, CA 95054 [email protected] Omnicell Announces Financial Results for Second Quarter 2022 GAAP revenues of $331 million and non-GAAP revenues of $332 million GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share |
|
| June 22, 2022 |
Calculation of Filing Fee Table EX-FILING FEES 2 exhibit10712022-06.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Omnicell, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amou |
|
| June 22, 2022 |
Omnicell, Inc. 2009 Equity Incentive Plan, as amended Exhibit 99.1 OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2009 APPROVED BY THE STOCKHOLDERS: MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 17, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2010 AMENDED BY THE BOARD OF DIRECTORS: MARCH 18, 2013 APPROVED BY THE STOCKHOLDERS: MAY 21, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 13, 2015 APPROVED |
|
| June 22, 2022 |
As filed with the Securities and Exchange Commission on June 22, 2022 As filed with the Securities and Exchange Commission on June 22, 2022 Registration No. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 590 East Middlefield Road, Mountain View, California 94043 (Address of Princi |
|
| May 26, 2022 |
EX-1.01 2 a2021formsdcmr.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2021 to December 31, 2021 Introduction This Conflict Minerals Report (the “Report”) of Omnicell, Inc. (“Omnicell” or the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3304 |
|
| April 28, 2022 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Announces Financial Results for First Quarter 2022 GAAP and non-GAAP revenues of $319 million GAAP net income per diluted share of $0.17 Non-GAAP net income per diluted share of $0.83 Launched innovative |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 7, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| March 1, 2022 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Announces Changes to its Board of Directors Omnicell Intends to Nominate Mary Garrett for Election to Board of Directors at 2022 Annual Meeting of Stockholders MOUNTAIN VIEW, Calif. ? March 1, 2022 - Omni |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| February 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| February 25, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Omnicell Pty Ltd Australia Omnicell (Beijing) Technology Co. Ltd China Omnicell GmbH Federal Republic of Germany Omnicell SAS France Omnicell S.r.l. Italy Omnicell India Private Limited India Omnicell B.V. Netherlands Omnicell Limited United Kingdom ateb, Inc. United States RxInnovation Inc. Unite |
|
| February 25, 2022 |
Offer letter between Omnicell, Inc. and Christine Mellon dated February 12, 2021 Exhibit 10.32 February 12, 2021 Christine Mellon Dear Christine, Omnicell Inc. is pleased to offer you the Executive Vice President and Chief People Officer position reporting to Randall Lipps. Your bi-weekly salary will be $13,076.92, less payroll deductions and all required and authorized withholdings, which is an annual equivalent of $340,000.00. You will be awarded, subject to approval by our |
|
| February 25, 2022 |
Omnicell, Inc. Board of Directors Compensation Plan Exhibit 10.33 OMNICELL, INC. BOARD OF DIRECTORS COMPENSATION PLAN That upon recommendation of the Compensation Committee, and after review and discussion, the Board of Directors? Board compensation, effective for 2021, shall be, and it is hereby approved as described below: ?Each non-employee member of the Board shall receive cash compensation in the amount of $22,500 per quarter at the time of an |
|
| February 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2022 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Reports Fiscal Year and Fourth Quarter 2021 Results 2021 Total Product Bookings of $1.217 billion Full Year 2021 Revenues of $1.132 billion Ended Year with 151 Long-Term, Sole-Source Agreements with the T |
|
| February 10, 2022 |
OMCL / Omnicell, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Omnicell Inc. Title of Class of Securities: Common Stock CUSIP Number: 68213N109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| February 4, 2022 |
OMCL / Omnicell, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Omnicell, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68213N109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 4, 2022 |
MarkeTouch Media January 4, 2022 Safe Harbor Statement 2? 2022 Omnicell, Inc. Content is confidential and proprietary. This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the outcome of the acquisition, the expected benefits of the acquisition of the MarkeTouch Media business, including the impact of the acquisition on Omnicell |
|
| January 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2022 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 4, 2022 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Carol Kimura Vice President, Investor Relations Vice President, Brand, Digital & Growth Marketing Omnicell, Inc. Omnicell, Inc. (650) 435-3318 (650) 251-6363 [email protected] [email protected] Omnicell Acquires MarkeTouch Media Strategic acquisition of pharmacy technology solutions provider expands and deepens EnlivenH |
|
| December 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| December 29, 2021 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Carol Kimura Vice President, Investor Relations Vice President, Commercial Marketing Omnicell, Inc. Omnicell, Inc. (650) 435-3318 (650) 251-6363 [email protected] [email protected] Omnicell Completes Acquisition of ReCept Addition of specialty pharmacy management services expands Advanced Services portfolio to support a |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| December 2, 2021 |
ReCept December 2, 2021 Safe Harbor Statement 2? 2021 Omnicell, Inc. Content is confidential and proprietary. This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing and outcome of the acquisition or its consummation, the expected benefits of the acquisition of the ReCept business, including the impact of the acquisition |
|
| December 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 2, 2021 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Carol Kimura Vice President, Investor Relations Vice President, Brand, Digital & Growth Marketing Omnicell, Inc. Omnicell, Inc. (650) 435-3318 (650) 251-6363 [email protected] [email protected] Omnicell to Acquire ReCept Strategic acquisition of leading specialty pharmacy management services provider supports the Autono |
|
| November 5, 2021 |
Amendment to Omnicell, Inc. 2009 Equity Incentive Plan AMENDMENT TO THE OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN WHEREAS, Omnicell, Inc., a Delaware corporation (the ?Company?), maintains the Omnicell, Inc. 2009 Equity Incentive Plan (the ?Plan?); WHEREAS, pursuant to Section 2(b) of the Plan, the Board of Directors of the Company (the ?Board?) has the authority to amend the Plan as it shall deem advisable, subject to any requirement of stockholder a |
|
| November 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000- |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 2, 2021 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Announces Financial Results for Third Quarter 2021 GAAP and non-GAAP revenues of $296 million GAAP net income per diluted share of $0.61 Non-GAAP net income per diluted share of $1.08 MOUNTAIN VIEW, Calif. - Nov |
|
| September 9, 2021 |
Exhibit 99.1 For more information, contact: Kathleen Nemeth Betsy Martinelli Omnicell, Inc. Omnicell, Inc. (650) 435-3318 (724) 741-8341 [email protected] [email protected] Omnicell Completes Acquisition of FDS Amplicare Expands nationwide footprint of retail pharmacy customers, adding industry-leading financial management, analytics, and population health solutions to Enliv |
|
| September 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 6, 2021 |
Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2020 to December 31, 2020 Introduction This Conflict Minerals Report (the ?Report?) of Omnicell, Inc. (?Omnicell? or the ?Company?) has been prepared pursuant to Rule 13p-1 (the ?Rule?) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), for the reporting period from January 1, |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 590 East Middlefield Road, Mountain View, California 94043 (Address of Princi |
|
| August 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| July 29, 2021 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Announces Financial Results for Second Quarter 2021 Record revenues of $273 million GAAP net income per diluted share of $0.43 Record non-GAAP net income per diluted share of $0.97 MOUNTAIN VIEW, Calif. - July 2 |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 26, 2021 |
Acquisition of FDS Amplicare Expands Omnicell?s EnlivenHealth Solutions Platform July 26, 2021 Safe Harbor Statement 2 This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the consummation of the acquisition, the expected benefits of the acquisition of the FDS Amplicare business, including on Omnicell?s non-GAAP earnings per share, the impact of the acquisition on Omnicell?s products and services and the capabilities of the products and services of the Fleming business. |
|
| July 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 26, 2021 |
EX-99.1 2 exhibit991-fdsamplicareacq.htm EX-99.1 Exhibit 99.1 For more information, contact: Kathleen Nemeth Betsy Martinelli Omnicell, Inc. Omnicell, Inc. (650) 435-3318 (724) 741-8341 [email protected] [email protected] Omnicell to Acquire FDS Amplicare Strategic acquisition of leading pharmacy SaaS solutions provider supports the Autonomous Pharmacy vision and expands Omn |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 12, 2021 |
Omnicell Appoints Edward Bousa to Board of Directors EX-99.1 2 exhibit991-directorapptxbo.htm EX-99.1 Exhibit 99.1 Omnicell Appoints Edward Bousa to Board of Directors 7/12/2021 MOUNTAIN VIEW, Calif. – (BUSINESS WIRE) – Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has increased its number of board seats from 9 to 10, and has appointed Edw |
|
| June 10, 2021 |
June 10, 2021 (File No. 333-256979) As filed with the Securities and Exchange Commission on June 10, 2021 Registration No. |
|
| June 10, 2021 |
Omnicell, Inc. 2009 Equity Incentive Plan, as amended Exhibit 99.1 OMNICELL, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2009 APPROVED BY THE STOCKHOLDERS: MAY 19, 2009 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 17, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2010 AMENDED BY THE BOARD OF DIRECTORS: MARCH 18, 2013 APPROVED BY THE STOCKHOLDERS: MAY 21, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 13, 2015 APPROVED |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3304 |
|
| April 29, 2021 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Announces Financial Results for First Quarter 2021 Record revenues of $252 million, an increase of 10% from the prior year period GAAP net income per diluted share of $0.30, Non-GAAP net income per diluted share |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2021 |
definitive proxy statement on Schedule 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 24, 2021 |
Exhibit 10.24 Execution Copy FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this ?First Amendment?) is entered into as of February April 8 , 2005, by and between the Multi-Employer Property Trust, a trust organized under 12 C.F.R. Section 9.18 (?Landlord?) and McKesson Automation Inc., a Pennsylvania corporation (?Tenant?), in consideration of the mutual covenants contained herein and the |
|
| February 24, 2021 |
Exhibit 10.25 SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this "Second Amendment") is entered into as of April 21, 2008, by and between NewTower Trust Company Multi-Employer Property Trust, a trust organized under 12 C.F.R. Section 9.18 and formerly known as the Multi Employer Property Trust ("Landlord") and McKesson Automation Inc., a Pennsylvania corporation ("Tenant"), in consider |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| February 24, 2021 |
Exhibit 10.22 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of this 28th day of September, 2012 (the "Effective Date"), by and between MIDDLEFIELD STATION ASSOCIATES, LLC, a Delaware limited liability company ("Landlord"), and OMNICELL, INC., a Delaware corporation ("Tenant"). RECITALS: A.Landlord and Tenant entered into that certain Le |
|
| February 24, 2021 |
Exhibit 10.10 Restricted Stock Unit Omnicell, Inc. Grant Notice 590 E. Middlefield, Mountain View, CA 94043 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (RSU) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Fair Market Value per Unit: Total |
|
| February 24, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Aesynt Pty Ltd Australia Omnicell Pty Ltd Australia Omnicell (Beijing) Technology Co. Ltd China Omnicell GmbH Federal Republic of Germany Omnicell SAS France Omnicell S.r.l. Italy Omnicell B.V. Netherlands Omnicell Limited United Kingdom ateb, Inc. United States MedPak Holdings, Inc. United States |
|
| February 24, 2021 |
FOURTH AMENDMENT TO LEASE THIS FOURTH. AMENDMENT TO LEASE (this "Fourth Amendment") is made as of the 29th day of October, 2013, between McKnight Cranberry III, L.P., a Delaware limited Partnership ("Landlord"), successor by assignment to Cranberry Cochran Road, L.P., a Delaware limited partnership, Cranberry Noble Land, L.P., a Delaware limited partnership, Cranberry Harmar Land, L.P., a Delaware |
|
| February 24, 2021 |
Third Amendment to Lease, dated January 11, 2011, between Cranberry Cochran Road, L.P., THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Third Amendment") is made as of the 11th day of January, 2011, between Cranberry Cochran Road, L. |
|
| February 24, 2021 |
Exhibit 10.9 Restricted Stock Unit Omnicell, Inc. Grant Notice 590 E. Middlefield, Mountain View, CA 94043 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (RSU) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Fair Market Value per Unit: Total P |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Omnicell Inc. Title of Class of Securities: Common Stock CUSIP Number: 68213N109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 1, 2021 |
exhibit9924q20earningsr 2020 Fiscal Year and Fourth Quarter Earnings Call February 1, 2021 Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of federal securities laws. |
|
| February 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 1, 2021 |
Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Vice President, Investor Relations 590 East Middlefield Road 650-435-3318 Mountain View, CA 94043 [email protected] Omnicell Reports Fiscal Year and Fourth Quarter 2020 Results Record 2020 Total Product Bookings of $1+ billion Full Year 2020 Revenues of $892.2 million Ended Year with 145 Long-Term, Sole-Source Agreements with the Top |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (C |
|
| January 13, 2021 |
Exhibit 99.1 Omnicell Announces Preliminary Fiscal Year 2020 Financial Results Company Expects to Exceed Previously Announced Guidance Across All Key Metrics; Provides Full Year 2021 Guidance and Updates Long-Term Targets 2020 Total Product Bookings Expected to be Approximately $1.00 Billion and 2020 Revenues Expected to be $890 Million-$892 Million Increased Full Year 2021 Preliminary Revenue Gui |
|
| January 13, 2021 |
Presentation entitled “Investor Update” dated January 13, 2021 Exhibit 99.2 Investor Update January 13, 2021 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to guidance, estimated full-year 2020 financial and operating results, 2025 targets, growth expectations and targets and other non-historical information. With |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2021 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (C |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Omnicell, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68213N109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| October 30, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000- |
|
| October 30, 2020 |
Exhibit 2.2 AMENDMENT NO. 1 to EQUITY PURCHASE AGREEMENT by and among: Omnicell, Inc., a Delaware corporation; and Charles Miller, as the Sellers’ Representative Dated October 1, 2020 Amendment No. 1 to Equity Purchase Agreement This Amendment No. 1 to Equity Purchase Agreement (this “Amendment”) is made and entered into on October 1, 2020 by and among: Omnicell, Inc., a Delaware corporation (“Pur |
|
| October 27, 2020 |
Exhibit 99.1 Contact: Peter Kuipers Omnicell, Inc. Chief Financial Officer 590 East Middlefield Road 800-850-6664 Mountain View, CA 94043 [email protected] Omnicell Reports Third Quarter 2020 Results GAAP and non-GAAP revenues of $213.7 million GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.60 MOUNTAIN VIEW, Calif. - October 27, 2020 - Omnicell, Inc |
|
| October 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (C |
|
| October 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Co |
|
| October 1, 2020 |
Exhibit 99.1 For more information, contact: Peter Kuipers Betsy Martinelli Omnicell, Inc. Omnicell, Inc. (650) 251-6100 (724) 741-8341 [email protected] [email protected] Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business Expands pharmacy inventory management capabilities for efficient, compliant management of 340B |
|
| September 25, 2020 |
Exhibit 4.1 OMNICELL, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 25, 2020 0.25% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions 1 Section 1.02 . References to Interest 14 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01 . Designation and Amount 14 Section 2.02 |
|
| September 25, 2020 |
Form of Convertible Note Hedge Confirmation Exhibit 10.1 [Dealer Name] [Dealer Address] [], 2020 To: Omnicell, Inc. 590 E. Middlefield Road Mountain View, CA 94043 Attention: Peter Kuipers, Executive Vice President and Chief Financial Officer Attention: Dan Johnston, Executive Vice President and Chief Legal and Administrative Officer Telephone No.: (650) 251-6100 Email: [email protected] and [email protected] Re: [Base][Additional] |
|
| September 25, 2020 |
Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY (THE “WARRANTS”) WERE ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE WARRANTS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQ |
|
| September 25, 2020 |
Exhibit 99.1 Omnicell, Inc. Prices $500 Million 0.25% Convertible Senior Notes Offering (up 37.5% Conversion Premium) September 23, 2020 MOUNTAIN VIEW, Calif.- Sep. 23, 2020 — Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced today the pricing of $500 million aggregate principal amount of 0.25% |
|
| September 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) |
|
| September 22, 2020 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “First Amendment”), dated as of September 22, 2020, is entered into by and among OMNICELL, INC., a Delaware corporation (the “Borrower”), each Subsidiary Guarantor (as defined in the Amended Credit Agreement (as defined below)) party hereto; ea |
|
| September 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) |
|
| September 22, 2020 |
Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes Exhibit 99.1 For more information, contact: Peter Kuipers Chief Financial Officer 800-850-6664 [email protected] Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes Mountain View, Calif., - September 22, 2020 –– Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacie |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 12, 2020 |
Exhibit 2.1 EQUITY PURCHASE AGREEMENT by and among: Omnicell, Inc., a Delaware corporation; PSGH, LLC, a Texas limited liability company; BW Apothecary Holdings, LLC, a Delaware limited liability company; The Sellers Set Forth on the Signature Pages Hereto; and Charles Miller, as the Sellers’ Representative Dated August 11, 2020 Table of Contents Page 1. Description of Transaction 2 1.1 Sale and P |
|
| August 12, 2020 |
Exhibit 99.1 For more information, contact: Peter Kuipers Betsy Martinelli Omnicell, Inc. Omnicell, Inc. (650) 251-6100 (724) 741-8341 [email protected] [email protected] Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business Expands pharmacy supply chain capabilities for efficient, compliant management of 340B programs Accelerates O |
|
| August 12, 2020 |
Second Amended and Restated Bylaws of Omnicell, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF OMNICELL, INC. (A DELAWARE CORPORATION) Effective as of August 6, 2020 TABLE OF CONTENTS ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS' MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 9 |
|
| August 12, 2020 |
exhibit992-investordeckx Acquisition of 340B Link Business Expands Omnicell’s Autonomous Pharmacy Portfolio August 12, 2020 Safe Harbor Statement This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the consummation of the acquisition, the expected benefits of the acquisition of the 340B Link business, including on Omnicell’s non-GAAP earnings per share, the impact of the acquisition on Omnicell’s products and services and the capabilities of the products and services of the 340B Link business. |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Com |
|
| July 31, 2020 |
Exhibit 10.1 Option Omnicell, Inc. Grant Notice 590 E. Middlefield Road Mountain View, CA 94043 Name: Employee ID: You have been granted an option to purchase Omnicell, Inc. Common Stock as follows: Type of Option: Grant No.: Stock Option Plan: 2009 Equity Incentive Plan Date of Grant: Total Number of Option Shares: Option Price per Share: Total Exercise Price of Option Shares: Early Exercise Allo |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| July 31, 2020 |
Exhibit 10.2 Restricted Stock Unit Omnicell, Inc. Grant Notice 590 E. Middlefield, Mountain View, CA 94043 Name: Employee ID: You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows: Type of Award: Restricted Stock Unit (RSU) Grant No.: Equity Incentive Plan: 2009 Equity Incentive Plan Date of Grant: Shares Subject to Award: Fair Market Value per Unit: Total P |
|
| July 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 28, 2020 |
Exhibit 99.1 Contact: Peter Kuipers Omnicell, Inc. Chief Financial Officer 590 East Middlefield Road 800-850-6664 Mountain View, CA 94043 [email protected] Omnicell Reports Second Quarter 2020 Results GAAP revenues of $199.6 million and net loss per diluted share of $0.10 Non-GAAP revenues $199.6 million and net income per diluted share of $0.37 Omnicell’s Response to Coronavirus (COVID-1 |
|
| May 27, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Commi |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Omnicell, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 000-33043 94-3166458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 590 East Middlefield Road, Mountain View, California 94043 (Address of Princi |
|
| May 27, 2020 |
Exhibit 1.01 Conflict Minerals Report of Omnicell, Inc. for the reporting period from January 1, 2019 to December 31, 2019 Introduction This Conflict Minerals Report (the “Report”) of Omnicell, Inc. (“Omnicell” or the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-3304 |
|
| May 8, 2020 |
OMCL / Omnicell, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Omnicell, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68213N109 (CUSIP Number) April 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 7, 2020 |
Exhibit 99.1 Contact: Peter Kuipers Omnicell, Inc. Chief Financial Officer 590 East Middlefield Road 800-850-6664 Mountain View, CA 94043 [email protected] Omnicell Reports First Quarter 2020 Results GAAP and non-GAAP revenues of $229.7 million, up 13.4% year-over-year GAAP net income per diluted share of $0.26, up 225.0% year-over-year Non-GAAP net income per diluted share of $0.66, up 8 |
|
| May 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 7, 2020 |
OMCL / Omnicell, Inc. DEF 14A - - DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2020 |
Omnicell, Inc. Board of Directors Compensation Plan Exhibit 10.34 OMNICELL, INC. BOARD OF DIRECTORS COMPENSATION PLAN That upon recommendation of the Compensation Committee, and after review and discussion, the Board of Directors’ Board compensation, effective for 2019, shall be, and it is hereby approved as described below: •Each non-employee member of the Board shall receive cash compensation in the amount of $22,500 per quarter at the time of an |
|
| February 26, 2020 |
Exhibit 10.39 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this “Sixth Amendment”) is made as of the 11th day of November, 2019, between McKnight Cranberry III, L.P., (“Landlord”), and Aesynt Incorporated (“Tenant”). WHEREAS, Landlord and Tenant are parties to that certain Lease dated December 21, 2001 (the “Original Lease”), a certain First Amendment to Lease dated April 8, 2005 (the “ |
|
| February 26, 2020 |
Description of Omnicell, Inc.’s Securities Registered Pursuant to Section 12 of the Exchange Act Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Omnicell, Inc. (“we,” “our,” “us,” or “Omnicell”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share (the “common stock”). The following summary sets |
|
| February 26, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Entity's name for conducting business Jurisdiction of incorporation Aesynt Pty Ltd. Australia Omnicell (Beijing) Technology Co., Ltd. China Mach 4 Automatisierungs Technik, GmbH Federal Republic of Germany Omnicell GmbH Federal Republic of Germany Omnicell SAS France Health Robotics S.r.l. Italy Aesynt S.r.l Italy Aruba S.r.l Italy Aesynt Holding Cooperatief U.A. |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2020 OMNICELL, INC. (Exact name of registrant as specified in its charter) Delaware 000-33043 94-3166458 (State or other jurisdiction of incorporation or organization) ( |
